Spyre Therapeutics (SYRE) EBT Margin (2015 - 2023)
Spyre Therapeutics (SYRE) posted EBT Margin of 31551.45% for Q2 2023, down 238.45% on a QoQ basis from 9322.22% in Q1 2023, and down 2798121.0% year-over-year from N/an in Q2 2022.
Spyre Therapeutics (SYRE) EBT Margin (2015 - 2023) Analysis & Trends
Spyre Therapeutics' EBT Margin history runs 7 years deep, the most recent figure standing at 31551.45% for Q2 2023.
- Quarterly EBT Margin fell 2798121.0% year-over-year to 31551.45% in Q2 2023, while the trailing twelve-month figure through Mar 2024 was 52933.58% (down 4623838.0% YoY) and the FY2023 annual result came in at 38241.08%, down 3463649.0% from the prior year.
- EBT Margin was 31551.45% for Q2 2023 at Spyre Therapeutics, down from 9322.22% in the prior quarter.
- Across five years, EBT Margin topped out at 49.2% in Q2 2021 and bottomed at 31551.45% in Q2 2023.
- A 3-year average of 7644.12% and a median of 3570.24% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin slumped 352104 bps — and 2023, when it slumped 2798121 bps.
- Spyre Therapeutics' EBT Margin stood at 560.46% in 2021, then tumbled by 1895 bps to 11180.95% in 2022, then plunged by 182 bps to 31551.45% in 2023.
- Business Quant data shows SYRE's EBT Margin at 31551.45% in Q2 2023, 9322.22% in Q1 2023, and 11180.95% in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Spyre Therapeutics | 257.83 Mn | 257.83 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -31,551.45% |
| Mar 31, 2023 | -9,322.22% |
| Dec 31, 2022 | -11,180.95% |
| Sep 30, 2022 | -10,599.43% |
| Jun 30, 2022 | -3,570.24% |
| Mar 31, 2022 | -1,794.13% |
| Dec 31, 2021 | -560.46% |
| Sep 30, 2021 | -169.01% |
| Jun 30, 2021 | -49.20% |
| Jun 30, 2018 | -407.57% |
| Mar 31, 2018 | -545.76% |
| Dec 31, 2017 | -604.11% |
| Sep 30, 2017 | -623.47% |
| Jun 30, 2017 | -447.60% |
| Mar 31, 2017 | -664.66% |
| Dec 31, 2016 | -474.02% |
| Sep 30, 2016 | -568.32% |
| Jun 30, 2016 | -394.83% |
| Mar 31, 2016 | -528.64% |
| Dec 31, 2015 | -430.22% |